FIELD: immunology.
SUBSTANCE: this invention relates to immunology. What is presented is an anti-human beta-amyloid antibody and its antigen-binding fragment. What is also presented is a method of treating a human or an animal. Antibody of the present invention and its antigen-binding fragment selectively bind beta-amyloid 1-42 peptide (Aβ1-42) human, but not beta-amyloid 1-40 peptide (Aβ1-40) of a human being. In this regard, they can be used as therapeutic agents for treating conditions associated with amyloidosis, such as Alzheimer's disease, macular degeneration, or to improve cognitive state or delay cognitive impairment in Alzheimer's disease or Down's disease.
EFFECT: antibodies to beta-amyloid are offered.
11 cl, 19 dwg, 16 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY TO AMYLOID BETA | 2013 |
|
RU2651486C2 |
| BINDING MOLECULE SPECIFIC FOR HER3, AND THEIR APPLICATIONS | 2012 |
|
RU2620068C2 |
| Aβ-PEPTIDE ANTIBODIES AND APPLICATION THEREOF | 2003 |
|
RU2341533C2 |
| BINDING MOLECULES SPECIFIC FOR CD73, AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2730665C2 |
| BINDING ELEMENTS WITH MODIFIED DIVERSIFIED BACKBONE DOMAINS | 2017 |
|
RU2778694C2 |
| SAFE AND FUNCTIONAL HUMANIZED ANTIBODIES | 2011 |
|
RU2607368C2 |
| ANTI-TNFRSF25 ANTIBODIES | 2017 |
|
RU2746314C2 |
| HUMANISED ANTIBODY | 2008 |
|
RU2538709C2 |
| HUMANIZED ANTIBODY TO BETA AMYLOID | 2013 |
|
RU2668161C2 |
| COMMON LIGHT CHAIN MOUSE | 2013 |
|
RU2683514C2 |
